Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Hadassah Medical Organization |
---|---|
Information provided by: | Hadassah Medical Organization |
ClinicalTrials.gov Identifier: | NCT00410345 |
Induction of midtrimester abortion includes cervical ripening and then contraction to induce uterine evacuation. There are several protocols, but most of them include using prostaglandins (PG). The disadvantages of using PG include uncomfortable side effects and limits of using it for women after cesarean section. Mifepristone is an antiprogesterone drug and been used for induction of abortion in first and second trimesters abortions. The aim of this study is to explore the effectiveness of Mifepristone for cervical ripening before high dose Oxytocin drip.
Condition | Intervention | Phase |
---|---|---|
Abortion, Missed |
Drug: Mifepristone |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | Cervical Rippening With Antiprogesterone in Midtrimester Abortions |
Estimated Enrollment: | 50 |
Study Start Date: | August 2004 |
Study Completion Date: | May 2008 |
The aim of this study is to explore the effectiveness of Mifepristone for cervical ripening before high dose Oxytocin drip in midtrimester abortions.
After informed consent, all the women will be randomized for Mifepristone or placebo. 48 hours later, high dose oxytocin drip will be started and we will examine the success rate to induce abortion, the duration from starting oxytocin till evacuation of uterus and side effects.
Ages Eligible for Study: | 18 Years to 45 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Israel | |
Hadassah Medical Organization | |
Jerusalem, Israel |
Principal Investigator: | Assaf Ben-Meir, MD | Hadassah Medical Organization, Jerusalem, Israel |
Study ID Numbers: | mifepristoneoxytocin-HMO-CTIL |
Study First Received: | December 11, 2006 |
Last Updated: | November 2, 2008 |
ClinicalTrials.gov Identifier: | NCT00410345 History of Changes |
Health Authority: | Israel: Israeli Health Ministry Pharmaceutical Administration |
Pregnancy Complications Abortion, Missed Contraceptive Agents Hormone Antagonists Contraceptives, Oral Hormones, Hormone Substitutes, and Hormone Antagonists |
Contraceptive Agents, Female Mifepristone Abortion, Spontaneous Contraceptives, Postcoital Hormones |
Abortifacient Agents, Steroidal Contraceptives, Postcoital, Synthetic Pregnancy Complications Abortion, Missed Contraceptive Agents Hormone Antagonists Contraceptives, Oral Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Contraceptive Agents, Female |
Mifepristone Reproductive Control Agents Luteolytic Agents Contraceptives, Postcoital Pharmacologic Actions Therapeutic Uses Abortifacient Agents Menstruation-Inducing Agents Contraceptives, Oral, Synthetic Abortion, Spontaneous |